Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-07-21 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia receives USPTO Notice of Allowance for composition of matter patent on antibody CAN10
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia AB announcing that the USPTO has issued a Notice of Allowance for a patent application related to their CAN10 antibody. This is a corporate announcement regarding intellectual property and business development. Since it does not fit into specific categories like financial reports, dividends, or management changes, and is a standard regulatory/corporate disclosure, it falls under the 'Regulatory Filings' (RNS) category.
2022-07-21 English
Cantargia erhåller Notice of Allowance från USPTO för produktpatent för antikroppen CAN10
Regulatory Filings Classification · 95% confidence The document is a press release from Cantargia AB announcing that they have received a 'Notice of Allowance' from the USPTO for a patent application regarding their CAN10 antibody. This is a corporate regulatory announcement regarding intellectual property and business development. Since it does not fit into specific categories like financial reports, dividends, or management changes, it falls under the general regulatory filing category.
2022-07-21 Swedish
Major Shareholding Notification 2022
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding for 'Swedbank Robur Fonder AB' in 'CANTARGIA AB'. It explicitly states the 'Reason for major shareholding notification Sell' and provides 'Before the transaction' and 'After the transaction' figures, including the resulting percentage of voting rights (4.91%). This structure is characteristic of a notification regarding a change in significant share ownership, which aligns with the definition for Major Shareholding Notification (MRQ). The document is not a full annual report (10-K), an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2022-07-19 English
Cantargia announces the terms of its fully covered rights issue
Share Issue/Capital Change Classification · 99% confidence The document is titled "Cantargia announces the terms of its fully covered rights issue" and details the subscription price, ratio, record date, and timeline for a Rights Issue, which is a method of raising capital by offering new shares to existing shareholders. This clearly falls under the definition of Capital/Financing Update (CAP). Although it mentions a prospectus will be published later, the current document is the announcement detailing the terms of the financing activity itself, not just the announcement of the report's publication (RPA) or a general regulatory filing (RNS). It is a specific announcement about a capital structure change/fundraising effort.
2022-07-18 English
Cantargia offentliggör villkoren för den fullt garanterade företrädesemissionen
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Cantargia AB, dated July 18, 2022, announcing the terms of a fully guaranteed rights issue ('företrädesemission') intended to raise approximately 250 MSEK. It details the subscription price (3.75 SEK), subscription ratio (2:3), key dates (record date, subscription period), and outlines the underwriting/guarantee commitments from various parties (Joint Global Coordinators, AP funds, etc.). This content directly relates to a company fundraising or capital structure change. Based on the definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it mentions a prospectus will be published later, the primary purpose of this specific document is to announce the terms of the capital raise itself, not just the announcement of the report (RPA) or a general regulatory filing (RNS).
2022-07-18 Swedish
Cantargia appoints Dr. Dominique Tersago as Chief Medical Officer
Board/Management Information Classification · 99% confidence The document is a press release announcing a specific change in senior personnel: the appointment of Dr. Dominique Tersago as Chief Medical Officer (CMO). This directly aligns with the definition for Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is not a financial report (10-K, IR, ER), a shareholder vote result (DVA), or a general regulatory filing (RNS), but a specific management announcement.
2022-07-08 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.